52
Participants
Start Date
May 1, 2017
Primary Completion Date
November 25, 2019
Study Completion Date
November 25, 2019
Paclitaxel
standard weekly paclitaxel in 28-day cycles
CB-839
CB-839 administered as oral tablets twice daily (BID)
Columbia University, New York
Magee Womens Hospital - UPMC, Pittsburgh
University of Pennsylvania, Philadelphia
Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
Washington Cancer Institute, Washington D.C.
Weinberg Cancer Institute at Franklin Square, Baltimore
Charleston Hematology Oncology Associates, Charleston
Greenville Health System (GHS) Cancer Institute, Greenville
Northwest Georgia Oncology, Marietta
Winship Cancer Institute - Emory University, Atlanta
University Cancer and Blood Center, Athens
University of Miami, Miami
Moffitt Cancer Center and Research Institute, Tampa
University of Alabama at Brimingham, Birmingham
University of South Alabama, Mitchell Cancer Institute, Mobile
West Cancer Center, Germantown
Henry Ford Hospital, Detroit
Froedtert and the Medical College of Wisconsin, Milwaukee
Saint Louis University, St Louis
Ochsner Clinic Foundation, New Orleans
Baylor College of Medicine, Houston
MD Anderson, Houston
Northwest Medical Specialties, PLLC, Tacoma
Yale Cancer Center, New Haven
JTCC at Hackensack UMC, Hackensack
Lead Sponsor
Calithera Biosciences, Inc
INDUSTRY